In 2025, IMUNON advanced enrollment in its Phase 3 OVATION 3 study investigating IMNN-001 combined with neoadjuvant and adjuvant chemotherapy for newly diagnosed advanced ovarian cancer. Sites across North America and Europe have enrolled over 70% of the planned 450 patients as of December 20, reflecting strong investigator engagement. This rapid recruitment, supported by positive safety profiles and compelling Phase 2 efficacy signals—including a 13-month median overall survival extension (HR 0.70) in the intent-to-treat population—positions the company to complete enrollment by mid-2026 and target a Biologics License Application submission in early 2027 for the HRD-positive subgroup.

Translational results from the ongoing minimal residual disease (MRD) study, conducted in partnership with Break Through Cancer, showed that IMNN-001 induces robust IL-12 expression (up to 5-fold increase in IL12A/IL12B transcripts) in tumor-associated macrophages, triggering interferon-gamma cascades and T cell activation. Preliminary clinical readouts reported a 30% decrease in MRD positivity rate versus control, a 25% higher complete response score at cytoreduction, and an estimated 18-month progression-free survival rate of 62% compared with 45% in the control arm. No serious immune-related adverse events or cytokine release syndrome were observed, underscoring a favorable benefit/risk profile critical for regulatory discussions.

Throughout 2025, IMUNON maintained cost controls, reducing cGMP manufacturing expenses by 20% through process optimization and securing $60 million in committed financing to fund OVATION 3 through key interim analyses. Cash runway now extends into Q4 2026, with an estimated $30 million allocated to HRD-positive subgroup expansion. Key 2026 milestones include interim efficacy reviews in Q2, presentations at ASCO and ESMO, translational data release from OVATION 2 tumor samples, and business development updates on TheraPlas platform partnerships targeting Asia-Pacific licensing opportunities.